LuisGarcía-‐Sevillano
150
103. Athanasakis, K.; Petrakis, I.; Kyriopoulo
in the
Treatment of Rheumatoid Arthritis: A S
tudies.
ISRNRheumatology, 2013. Disponibleen:
.
104. Kawalec, P.; Mikrut, A.; Wiśniewska, N.;
novel
Janus kinase inhibitor, in the treatment
w and
meta-‐analysis. ClinRheumatol 32, 1415-‐1424(2013).
105. Jin, X.; Ding, C. Belimumab -‐ An anti-‐BLyS human monoclonal antibody for rheumatoid
arthritis. ExpertOpiniononBiological Therapy13, 315-‐322(2013).
106. Kurrasch, R.; Brown, J.C.; Chu, M.; Craigen, J.; Overend, P.; Patel, B.; et al. Subcutaneously
administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety,
tolerability, pharmacokinetics, and pharmacodynamics. J Rheumatol 40, 1089-‐1096
(2013).
107. Combe, B.; van Vollenhoven, R. Novel targeted therapies: the future of rheumatoid
arthritis?Mavrilumaband tabalumabas examples. AnnRheumDis72, 1433-‐1435(2013).
108. Genovese, M.C.; Fleischmann, R.M.; Greenwald, M.; Satterwhite, J.; Veenhuizen, M.; Xie, L.;
et al. Tabalumab, an anti-‐BAFF monoclonal antibody, in patients with active rheumatoid
arthritis with an inadequate response to TNF inhibitors. Ann RheumDis72, 1461-‐1468
(2013).
109. GómezReino, J.; Loza, E.; Andreu, J. L.; Balsa, A.; Batlle, E.; Cañete, J. D.; et al. ConsensoSER
sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con
enfermedades reumáticas. Reumatol Clin7, 284-‐298(2011).
110. UmićevićMirkov, M.; Coenen, M.J. Pharmacogenetics of disease-‐modifying antirheumatic
drugs in rheumatoid arthritis: towards personalized medicine. Pharmacogenomics
14,425-‐444(2013).
